Loading
Led SPEARHEAD-1, the trial that made afami-cel the first engineered TCR T-cell therapy approved for a solid tumour.
Sandra D'Angelo was principal investigator of SPEARHEAD-1, which showed the MAGE-A4-directed TCR T-cell therapy afamitresgene autoleucel produces durable responses in synovial sarcoma and led to its 2024 approval, the first engineered T-cell therapy for a solid tumour. She also led the JAVELIN Merkel 200 trial that won avelumab approval in Merkel cell carcinoma and leads cellular therapy trials in sarcoma at MSKCC.
Shares MAGE-A4, Afamitresgene autoleucel, SPEARHEAD-1: afamitresgene autoleucel, the first engineered T-cell receptor therapy approved for a solid tumour, in synovial sarcoma, TCR-T cell therapy.
Shares Afamitresgene autoleucel, SPEARHEAD-1: afamitresgene autoleucel, the first engineered T-cell receptor therapy approved for a solid tumour, in synovial sarcoma, Sarcomas (soft tissue, bone, GIST).
Shares Afamitresgene autoleucel, TCR-T cell therapy, Sarcomas (soft tissue, bone, GIST).
Shares Memorial Sloan Kettering Cancer Center, Sarcomas (soft tissue, bone, GIST) and the tag sarcoma.
Shares TCR-T cell therapy and the tag tcr-t.
Shares MAGE-A4, TCR-T cell therapy.
Shares Sarcomas (soft tissue, bone, GIST) and the tag sarcoma.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/